[Clinical Effect of Tacrolimus Combined with Glucocorticoid in the Treatment of IgA Nephropathy in Children]

Overview

Journal Zhongguo Dang Dai Er Ke Za Zhi

Specialty Pediatrics

Date 2019 Mar 26

PMID 30907352

Citations 1

Authors

Jian-Jiang Zhang

Qin Wang

Wen-Jie Dou

Li-Min Jia

Li Zhang

Yi-Bo Cheng

Wen-Xiu Tan

Fan Zhao

Affiliations

Soon will be listed here.

Abstract

Objective: To study the clinical effect and safety of tacrolimus (TAC) combined with glucocorticoid (GC) versus mycophenolate mofetil (MMF) combined with GC in the treatment of primary IgA nephropathy (IgAN) in children.

Methods: A retrospective analysis was performed for the clinical data of children with primary IgAN confirmed by renal pathology between January 2012 and December 2017. These children were divided into TAC group and MMF group according to the treatment regimen. Their clinical data before treatment and at 1, 3, and 6 months of treatment were collected, and the remission status of IgAN and adverse reactions were compared between the two groups.

Results: A total of 43 children who met the inclusion criteria were enrolled, with 15 children in the TAC group and 28 children in the MMF group. At 1 month of treatment, there was no significant difference in the remission status between the two groups (P>0.05). At 3 and 6 months of treatment, the TAC group had a significantly better remission status than the MMF group (P<0.05). At 1 month of treatment, the TAC group had higher serum albumin levels than the MMF group (P<0.05). Both groups had a significant increase in serum albumin levels at each time point after treatment (P<0.0083) and a significant increase in the glomerular filtration rate (GFR) at 3 and 6 months of treatment (P<0.0083). There was no significant difference in the overall incidence rate of adverse reactions between the two groups (P>0.05), but fungal infection was observed in one child from the TAC group.

Conclusions: TAC combined with GC can effectively reduce urinary protein in children with primary IgAN, and it has a better short-term clinical effect than MMF combined with GC, with good safety.

Citing Articles

Management of IgA Nephropathy in Pediatric Patients.

Schroda S, Pohl M Children (Basel). 2022; 9(5).

PMID: 35626829 PMC: 9139388. DOI: 10.3390/children9050653.

References

Penfold R, Prendecki M, McAdoo S, Wk Tam F . Primary IgA nephropathy: current challenges and future prospects. Int J Nephrol Renovasc Dis. 2018; 11:137-148. PMC: 5905843. DOI: 10.2147/IJNRD.S129227. View

Zhang Y, Luo J, Hu B, Ma T . Efficacy and safety of tacrolimus combined with glucocorticoid treatment for IgA nephropathy: a meta-analysis. J Int Med Res. 2018; 46(8):3236-3250. PMC: 6134674. DOI: 10.1177/0300060518776566. View

Berger J, HINGLAIS N . [Intercapillary deposits of IgA-IgG]. J Urol Nephrol (Paris). 1968; 74(9):694-5. View

Loeffler K, Gowrishankar M, Yiu V . Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol. 2004; 19(3):281-7. DOI: 10.1007/s00467-003-1370-3. View

Lee H, Lee M, Lee S, Lee S, Lee E, Lee E . Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee's glomerular grading system. Nephrol Dial Transplant. 2004; 20(2):342-8. DOI: 10.1093/ndt/gfh633. View

Hu T, Liu Q, Xu Q, Liu H, Qiu W, Huang F . Tacrolimus decreases proteinuria in patients with refractory IgA nephropathy. Medicine (Baltimore). 2018; 97(18):e0610. PMC: 6392720. DOI: 10.1097/MD.0000000000010610. View

Supavekin S, Surapaitoolkorn W, Kurupong T, Chaiyapak T, Piyaphanee N, Pattaragarn A . Tacrolimus in steroid resistant and steroid dependent childhood nephrotic syndrome. J Med Assoc Thai. 2013; 96(1):33-40. View

Yang E, Lee S, Choi H, Cho H, Lee J, Kang H . Tacrolimus for children with refractory nephrotic syndrome: a one-year prospective, multicenter, and open-label study of Tacrobell®, a generic formula. World J Pediatr. 2015; 12(1):60-5. DOI: 10.1007/s12519-015-0062-y. View

He L, Peng Y, Liu H, Liu Y, Yuan S, Liu F . Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids. J Nephrol. 2012; 26(3):564-71. DOI: 10.5301/jn.5000199. View

10.

Zhang Q, Shi S, Zhu L, Lv J, Liu L, Chen Y . Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy. Am J Nephrol. 2012; 35(4):312-20. DOI: 10.1159/000337175. View

11.

Yeo S, Cheung C, Barratt J . New insights into the pathogenesis of IgA nephropathy. Pediatr Nephrol. 2017; 33(5):763-777. PMC: 5861174. DOI: 10.1007/s00467-017-3699-z. View

12.

Chen W, Liu Q, Liao Y, Yang Z, Chen J, Fu J . Outcomes of tacrolimus therapy in adults with refractory membranous nephrotic syndrome: a prospective, multicenter clinical trial. Am J Med Sci. 2012; 345(2):81-7. DOI: 10.1097/MAJ.0b013e31824ce676. View

13.

Zheng J, Bi T, Zhu L, Liu L . Efficacy and safety of mycophenolate mofetil for IgA nephropathy: An updated meta-analysis of randomized controlled trials. Exp Ther Med. 2018; 16(3):1882-1890. PMC: 6122311. DOI: 10.3892/etm.2018.6418. View

14.

Zhao Y, Zhu L, Liu L, Shi S, Lv J, Zhang H . Measures of Urinary Protein and Albumin in the Prediction of Progression of IgA Nephropathy. Clin J Am Soc Nephrol. 2016; 11(6):947-955. PMC: 4891752. DOI: 10.2215/CJN.10150915. View

15.

Floege J, Eitner F . Current therapy for IgA nephropathy. J Am Soc Nephrol. 2011; 22(10):1785-94. DOI: 10.1681/ASN.2011030221. View

16.

Li C, Li L . Tacrolimus in preventing transplant rejection in Chinese patients--optimizing use. Drug Des Devel Ther. 2015; 9:473-85. PMC: 4298305. DOI: 10.2147/DDDT.S41349. View

17.

Trimarchi H, Barratt J, Cattran D, Cook H, Coppo R, Haas M . Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017; 91(5):1014-1021. DOI: 10.1016/j.kint.2017.02.003. View

18.

Liu X, Dewei D, Sun S, Xu G, Liu H, He L . Treatment of severe IgA nephropathy: mycophenolate mofetil/prednisone compared to cyclophosphamide/prednisone. Int J Clin Pharmacol Ther. 2013; 52(2):95-102. DOI: 10.5414/CP201887. View

19.

Scalea J, Levi S, Ally W, Brayman K . Tacrolimus for the prevention and treatment of rejection of solid organ transplants. Expert Rev Clin Immunol. 2015; 12(3):333-42. DOI: 10.1586/1744666X.2016.1123093. View